Serum Levels of Amitriptyline and Therapeutic Effect in Non-Delusional Moderately to Severely Depressed In-Patients: a Therapeutic Window Relationship

 

 Buy Article Permissions and Reprints

In a prospective, open clinical study, the relationship between serum levels of amitriptyline (At) and nortriptyline (Nt) and the therapeutic effect after 6 weeks of treatment was investigated. Serum levels were measured by gas-liquid chromatography and the therapeutic effect was assessed by the Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression Scale (CGI). A number of 25 non-delusional, moderate to severely depressed inpatients were included. A therapeutic window relationship was detected by means of regression analysis (quadratic model). Low and high serum levels were associated with low therapeutic effect. In an intermediate range, the probability of good therapeutic effect was increased. This relationship reached significance for the serum levels of At (p < 0.05) and a trend for the sum of serum levels of At and Nt (p < 0.1). As expressed by the regression coefficient r², about 25 % to 35 % of the variability of therapeutic effect was explained by serum levels. Dichotomized data sets according to limits of final values of HAMD and CGI as well as limits of a therapeutic window of 70 ng/ml and 200 ng/ml (sum of At and Nt) revealed significant differences by means of Fisher's exact test (p < 0.05). Furthermore, increased ratios of serum level of Nt per serum level of At were found to be associated with decreased therapeutic effect. Thus, the present data support the existence of a therapeutic window of serum levels of At in depression. Also taking into account other reports, this therapeutic window can be defined as being between about 70 and 220 ng/ml. The assay of serum levels of At can be used to lower the risk of unsatisfactory therapeutic outcome.

References

• 1 Altman D G, Bland J M. Absence of evidence is not evidence of absence.  Brit Med J. 1995;  311 485
  Google Scholar
• 2 Baumann P, Jonzier-Perey M, Koeb L, Le P K, Tinguely D, Schöpf J. Amitriptyline pharmacokinetics and clinical response: free and total plasma amitriptyline and nortriptyline.  Int Clin Psychopharmacol. 1986;  1 89-101
  PubMedGoogle Scholar
• 3 Boyer W F, Lake R. Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response: a statistical review.  J Clin Psychopharmacol. 1987;  7 67-71
  PubMedGoogle Scholar
• 4 Braithwaite R, Goulding T, Theano G, Bailey J, Coppen A. Plasma concentration of amitriptyline and clinical response.  Lancet. 1972;  1 1297-1300
  PubMedGoogle Scholar
• 5 Breyer-Pfaff U, Gaertner H J, Giedke H. Plasma levels, psychophysiological variables, and clinical response to amitriptyline.  Psychiat Res. 1982a;  6 223-234
  CrossrefPubMedGoogle Scholar
• 6 Breyer-Pfaff U, Gaertner H J, Kreuter F, Scharek G, Brinkschulte M, Wiatr R. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels.  Psychopharmacol. 1982b;  76 240-244
  PubMedGoogle Scholar
• 7 Breyer-Pfaff U, Giedke H, Gaertner H J, Nill K. Validation of a therapeutic plasma level range in amitriptyline treatment of depression.  J Clin Psychopharmacol. 1989;  9 116-121
  PubMedGoogle Scholar
• 8 Burke M J, Preskorn S H. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ (eds.) Psychopharmacology: The 4th generation of progress. New York; Raven 1995: 1053-1065
  Google Scholar
• 9 Collegium Internationale Psychiatriae Scalarum (CIPS) .Internationale Skalen für Psychiatrie. Göttingen; Münch 1996: 93-149
  Google Scholar
• 10 Coppen A, Ghose K, Montgomery S, Rama Rao V A, Bailey J, Christiansen J. et al . Amitriptyline plasma concentration and clinical effect.  Lancet. 1978;  14 63-66
  PubMedGoogle Scholar
• 11 Coppen A, Ghose K, Jorgensen A. Pharmacokinetics and pharmacodynamics of amitriptyline in depression.  Progr Neuro-Psychopharmacol. 1979;  3 191-199
  PubMedGoogle Scholar
• 12 Corona G L, Cucchi M L, Fratini P, Santagostino G, Schinelli S, Zerbi F, Savoldi F. Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression.  Psychopharmacol (Berl.). 1990;  100 334-338
  PubMedGoogle Scholar
• 13 Corona G L, Fenoglia L, Pinelli P, Zerbi F. Amitriptyline and nortriptyline plasma levels and therapeutic response in depressed women.  Pharmacopsychiat. 1977;  10 299-308
  PubMedGoogle Scholar
• 14 De Oliveira I R, Do Prado-Lima P AS, Samuel-Lajeunesse B. Monitoring of tricyclic antidepressant plasma levels and clinical response: a review of the literature. Part 1.  Psychiat & Psychobiol. 1989;  4 43-60
  PubMedGoogle Scholar
• 15 Danish University Antidepressant Group (DUAG) .Clomipramine dose-effect study in patients with depression: Clinical endpoints and pharmacokinetics. Clin Pharmacol Ther 1999 66: 152-165
  Google Scholar
• 16 Faltermaier-Temizel M, Laakmann G, Baghai T, Kuhn K. Predictive factors for therapeutic success in depressive syndrome.  Nervenarzt. 1997;  68 62-68
  CrossrefPubMedGoogle Scholar
• 17 Galuszko P, Jakitowicz J, Landowski J, Nowicki Z. Plasma amitriptyline levels and its therapeutic effect in endogenous depression.  Psychiatr Pol. 1987;  21 110-114
  PubMedGoogle Scholar
• 18 Garaj V, Frank V, Drimalova M, Moric R, Pullman R. Relation of plasma amitriptyline and nortriptyline levels to the therapeutic response in endogenous depression.  Cesk Psychiatr. 1986;  82 307-312
  PubMedGoogle Scholar
• 19 Glassman A H, Schildkraut J J, Orsulak P J, Cooper T B, Kupfer D J, Shader R I. et al . Tricyclic antidepressants - blood level measurements and clinical outcome: An APA task force report.  Am J Psychiatr. 1985;  142 155-162
  PubMedGoogle Scholar
• 20 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: Methods and first results for tricyclic antidepressants and SSRI.  Pharmacopsychiat. 1999;  32 21-28
  PubMedGoogle Scholar
• 21 Hirschfeld R MA. Psychosocial predictors of outcome in depression. In: Bloom FE, Kupfer DJ (eds.) Psychopharmacology: The 4th generation of progress. New York; Raven 1995: 1113-1121
  Google Scholar
• 22 Jakitowicz J. The amitriptyline plasma levels and therapeutic response in patients with affective illness.  Psychiat Pol. 1991;  25 14-20
  PubMedGoogle Scholar
• 23 Janicak P G, Javaid J I, Davis J M. Neuroleptic plasma levels: Methodological issues, study design, and clinical applicability. In: Marder SR, Davis JM, Janicak PG (eds.) Clinical use of neuroleptic plasma levels. Washington, London; Am Psych Press 1993: 17-44
  Google Scholar
• 24 Jungkunz G, Kuß H J. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients.  Pharmakopsychiat. 1980;  13 111-116
  PubMedGoogle Scholar
• 25 Kocsis J H, Hanin I, Bowden C, Brunswick D. Imipramine and amitriptyline plasma concentrations and clinical response in major depression.  Brit J Psychiat. 1986;  148 52-57
  PubMedGoogle Scholar
• 26 Kupfer D J, Hanin I, Spiker D, Neil J, Coble P, Grau T, Nevar C. Amitriptyline plasma levels and clinical response in primary depression: II. Commun.  Psychopharmacol. 1978;  2 441-450
  PubMedGoogle Scholar
• 27 Liisberg P, Mose H, Amdisen A, Jorgensen A, Hopfner Petersen H E. A clinical trial compairing sustained release amitriptyline (Amitriptyline, retard) and conventional amitriptyline tablets (Amitriptylin) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline.  Acta Psychiat Scand. 1978;  57 426-435
  PubMedGoogle Scholar
• 28 Liu P. Relation of plasma levels and clinical response to amitriptyline in treating endogenous depression.  Chung Hua Shen Ching Ching Shen Ko Tsa Chih. 1988;  21 263-266, 318
  PubMedGoogle Scholar
• 29 Lohse M J, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D (eds.)
• 30 Arzneiverordnungsreport 1998. Berlin; Springer 1998: 455-478
  Google Scholar
• 31 Meador-Woodruff J H, Akil M, Wisner-Carlson R, Grunhaus L. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels.  J Clin Psychopharmacol. 1988;  8 28-32
  PubMedGoogle Scholar
• 32 Meador-Woodruff J H, Grunhaus L. Profound behavioral toxicity due to tricyclic antidepressants.  J Nerv Ment Dis. 1986;  174 628-630
  PubMedGoogle Scholar
• 33 Mendlewicz J, Linkowski P, Rees J A. A double-blind comparison of dothiepin and amitriptylin in patients with primary affective disorder: serum levels and clinical response.  Br J Psychiat. 1980;  136 154-160
  PubMedGoogle Scholar
• 34 Miljkovic B, Pokrajac M, Timotijevic I, Varagic V. Clinical response and plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients.  Eur J Drug Metab Pharmacokinet. 1996;  21 251-255
  PubMedGoogle Scholar
• 35 Montgomery S A, McAuley R, Rani S J, Montgomery D B, Braithwaite R, Dawling S. Amitriptyline plasma concentrations and clinical response.  Br Med J. 1979;  27(1)(6158) 230-231
  PubMedGoogle Scholar
• 36 Moyes I C, Ray R L, Moyes R B. Plasma levels and clinical improvement - a comparative study of clomipramine and amitriptyline in depression.  Postgrad Med J. 1980;  56 (Suppl 1) 127-129
  PubMedGoogle Scholar
• 37 Nierenberg A A, McLean N E, Alpert J E, Worthington J J, Rosenbaum J F, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.  Am J Psychiat. 1995;  152 1500-1503
  PubMedGoogle Scholar
• 38 Perry P J, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response.  J Clin Psychopharmacol. 1994;  14 230-240
  PubMedGoogle Scholar
• 39 Pidrman V, Krpalek P. Levels of amitriptyline and its metabolites in the treatment of depression.  Cesk Psychiatr. 1991;  87 209-218
  PubMedGoogle Scholar
• 40 Preskorn S H. Factors affecting the biphasic concentration - effect relationships of tricyclic antidepressants. In: Dahl S, Usdin E (eds.) Clinical Pharmacology in Psychiatry. London; Mc Millan 1981: 297-306
  Google Scholar
• 41 Preskorn S H, Fast G A. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.  J Clin Psychiat. 1991;  52(6) (Suppl) 23-33
  PubMedGoogle Scholar
• 42 Preskorn S H, Fast G A. Tricyclic antidepressant-induced seizures and plasma drug concentrations.  J Clin Psychiat. 1992;  53 160-162
  PubMedGoogle Scholar
• 43 Preskorn S H, Simpson S. Tricyclic-antidepressant-induced delirium and plasma drug concentration.  Am J Psychiat. 1982;  139 822-823
  PubMedGoogle Scholar
• 44 Prien R F, Kocsis J H. Long-term treatment of mood disorders. In: Bloom FE, Kupfer DJ (eds.) Psychopharmacology: The 4th generation of progress. New York; Raven 1995: 1067-1079
  Google Scholar
• 45 Reynolds C F, Perel J M, Frank E, Cornes C, Miller M D, Houck P R,. et al . Three-year outcomes of maintenance nortriptyline treatment in late-life depression: A study of two fixed plasma levels.  Am J Psychiat. 1999;  156 1177-1181
  PubMedGoogle Scholar
• 46 Robinson D S, Cooper T B, Ravaris C L, Ives J O, Nies A, Bartlett D, Lamborn K R. Plasma tricyclic drug levels in amitriptyline-treated depressed patients.  Psychopharmacol. 1979;  63 223-231
  PubMedGoogle Scholar
• 47 Schmauss M, Erfurth A. Prediction of antidepressant response - Critical review and perspectives.  Fortschr Neurol Psychiat. 1993;  61 274-283
  PubMedGoogle Scholar
• 48 Shimoda K, Yasuda S, Morita S, Shibasaki M, Someya T, Bertilsson L, Takahashi S. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state.  Psychiat and Clin Neurosci. 1997;  51 35-41
  PubMedGoogle Scholar
• 49 Stolley P D, Strom B L. Sample size calculations for clinical pharmacology studies.  Clin Pharmacol Ther. 1986;  39 489-490
  PubMedGoogle Scholar
• 50 Teicher M H, Baldessarini R J. Selection of neuroleptic dosage.  Arch Gen Psychiat. 1985;  42 636-637
  PubMedGoogle Scholar
• 51 Ulrich S, Isensee T, Pester U. Simultaneous determination of amitriptyline, nortriptyline and 4 hydroxylated metabolites in serum by capillary gas-liquid chromatography with nitrogen-phosphorus selective detection.  J Chromatogr B. 1996;  685 81-89
  PubMedGoogle Scholar
• 52 Ulrich S, Wurthmann C, Brosz M, Meyer F P. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: A review.  Clin Pharmacokin. 1998;  34 227-263
  PubMedGoogle Scholar
• 53 Vandel S, Vandel B, Sandoz M, Allers G, Bechtel P, Volmat R. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.  Eur J Clin Pharmacol. 1978;  14 185-190
  PubMedGoogle Scholar
• 54 Van Putten T, Marder S R. Variable dose studies provide misleading therapeutic windows.  (Letter) J Clin Psychopharmacol. 1986;  6 55-56
  PubMedGoogle Scholar
• 55 Ziegler V E, Co B T, Taylor J R, Clayton P J, Biggs J T. Amitriptyline plasma levels and therapeutic response.  Clin Pharmacol Ther. 1976;  19 795-801
  PubMedGoogle Scholar
• 56 Zhang X. Serum concentrations of amitriptyline and its metabolites and clinical effect in depressive patients.  Chung Hua Shen Ching Ching Shen Ko Tsa Chih. 1992;  25 196-198, 252
  PubMedGoogle Scholar

Dr. Sven Ulrich

Institute of Clinical Pharmacology,
University Hospital Magdeburg

Leipziger Straße 44,

39120 Magdeburg

Germany

Phone: + 49 391/6713060

Fax: + 49 391/6713062